|drug1647||Interleukin 6 (IL6) Antagonist Wiki||1.00|
|drug1648||Interleukin 6 (IL6) Antagonist and corticosteroids Wiki||1.00|
|D016638||Critical Illness NIH||0.13|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
The aim of this study is to determine if Povidone iodine (PVP-I) rinses and throat gargles or a PVP-I gel forming nasal spray compared to a placebo (a treatment that has no physical effect to a person) is an effective treatment for patients diagnosed with COVID-19. These patients have been diagnosed with mild/moderate COVID-19 symptoms and sent home for self-isolation. Patients will be instructed to take either of the two treatments or placebo twice daily for two weeks and have follow up visits 2 and 4 weeks after. The participants will also complete study related procedures such as saliva sample collection, and two questionnaires throughout the study period. The investigators hypothesize that COVID 19 positive participants who use either of the Povidone - Iodine treatment will have a reduction in their viral load, develop a negative oral mucosa sample and improve their clinical symptoms.
Description: A saliva sample will be analyzed to monitor the duration of positivity and when test becomes negative for SARS-CoV-2.Measure: Change in SARS-CoV-2 positivity in the saliva Time: A saliva sample will be taken every 2 days for 2 weeks, and again at 4 and 6 weeks
Description: Quantify the amount of SAR-CoV-2 viral load present in the saliva.Measure: Change in the SAR-CoV-2 viral load in the saliva Time: A saliva sample will be taken every 2 days for 2 weeks, and again at 4 and 6 weeks
Description: This is a 44 question, quality of life survey designed to measure different aspects affected by the common cold.Measure: Change in Wisconsin Upper Respiratory Symptom Survey (WURSS-44) Time: daily for 2 weeks, 4 weeks, and 6 weeks
Description: That includes 22 questions about symptoms and social/emotional consequences of your nasal disorder.Measure: Change Sino nasal Outcome Test (SNOT-22) Time: baseline, 2 weeks, 4 weeks, 6 weeks
Description: We will record and worsening of clinical condition such as, need for hospitalization/oxygen support.Measure: Change in clinical condition Time: daily for 2 weeks, 4 weeks, and 6 weeks
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports